What is Bioptix?
Bioptix is dedicated to providing a comprehensive suite of reagents and assay kits essential for diverse biological research applications, including cancer studies and diagnostic testing. Their product portfolio encompasses vital tools such as assay kits, PCR reagents, and specialized cell lines, serving researchers across oncology, immunology, and molecular biology. By equipping scientists and healthcare professionals with high-quality instruments, Bioptix aims to enhance research efficiency and diagnostic accuracy. The company's commitment extends to academic institutions, clinical laboratories, and pharmaceutical firms, all of whom rely on Bioptix to further scientific knowledge and improve patient outcomes.
How much funding has Bioptix raised?
Bioptix has raised a total of $22.7M across 8 funding rounds:
Unspecified
$3.4M
Unspecified
$1.2M
Unspecified
$4.5M
Unspecified
$6.2M
Private Equity
$2.1M
Private Equity
$1.4M
Private Equity
$1.5M
Private Equity
$2.5M
Unspecified (2009): $3.4M with participation from Boulder Ventures
Unspecified (2010): $1.2M, investors not publicly disclosed
Unspecified (2011): $4.5M supported by Boulder Ventures
Unspecified (2013): $6.2M, investors not publicly disclosed
Private Equity (2014): $2.1M, investors not publicly disclosed
Private Equity (2014): $1.4M with participation from Boulder Ventures, Rusnano, and Remeditex
Private Equity (2015): $1.5M, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Key Investors in Bioptix
Boulder Ventures
Boulder Ventures is a venture capital firm with a specialization in IT and biotech companies, particularly those located in Colorado and the Mid-Atlantic region. They have a proven track record of supporting innovative startups, evidenced by numerous successful exits and IPOs.
Rusnano
Rusnano focuses on the development and optimization of advanced technologies, including microelectronics and biotechnology, aiming to support various industries with innovative solutions. They are actively involved in equipping enterprises and promoting advanced technologies.
Remeditex
Remeditex seeks to develop early-stage biomedical science opportunities, aiming to make Texas and Colorado preferred locations for biotechnology companies by accelerating commercialization and attracting venture capital.
What's next for Bioptix?
The recent major strategic investment in Bioptix signals a pivotal moment for the company, likely enabling accelerated expansion of its product development pipeline and market reach. With a history of consistent capital infusion, Bioptix is well-positioned to solidify its standing in the competitive life sciences sector. Future endeavors may include the development of novel assays, the enhancement of existing product lines, and strategic partnerships to broaden its impact in diagnostic testing and therapeutic research. The company's focus on supporting scientific advancement suggests a trajectory aimed at becoming an indispensable partner for researchers globally.
See full Bioptix company page
